NZYM B Novozymes A/S Class B

Invitation to the annual shareholders’ meeting

Invitation to the annual shareholders’ meeting

The annual shareholders’ meeting will be held on

Tuesday April 30, 2024 at 4:00 pm CET at Bella Center, Center Boulevard 5, Denmark.

The distribution of profit will be addressed at the meeting and the Board of Directors proposes an ordinary dividend of DKK 2 or EUR 0.27 per A/B share for the last four months (September 1 - December 31) of 2023. This equals a pay-out ratio of 53.2% of Novonesis’ adjusted net profit for the four-month period.

Following the approval of the proposed dividend, legacy Novozymes shareholders will have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share (50.8% pay-out ratio). This equals an increase in the paid dividend of 3% compared to the dividend paid for the 2022 result.

The invitation to convene the annual shareholders’ meeting is attached in English and Danish.

Attachments



EN
08/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management Please read the full announcement in PDF Attachment

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management Please read the full announcement in PDF Attachment

 PRESS RELEASE

Major shareholder announcement

Major shareholder announcement Please read the full announcement in PDF Attachments

 PRESS RELEASE

Novonesis delivered 8% organic sales growth in the first nine months o...

Novonesis delivered 8% organic sales growth in the first nine months of 2025 Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards.  COPENHAGEN, Denmark – November 6, 2025. Novonesis delivered 8% organic sales growth in the first nine months of 2025. Full-year outlook is narrowed upwards to 7-8%, previously 6-8%. Ester Baiget, President & CEO:  "I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability. Our performance was strong across all sales areas and i...

 PRESS RELEASE

8% organic sales growth after first nine months. Full-year organic sal...

8% organic sales growth after first nine months. Full-year organic sales growth narrowed upwards. Ester Baiget, President & CEO: ”I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability and cash flow. Our performance was strong across all sales areas and in Emerging and Developed Markets. We delivered 37.3% adjusted EBITDA margin, despite significant currency headwinds, demonstrating the strength and resilience of our business model. Following a robust nine-months performance including favorable timing in the third quar...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch